- Report
- April 2020
- 119 Pages
Global
From €3506EUR$3,660USD£2,985GBP
- Report
- May 2018
- 106 Pages
Global
From €3352EUR$3,500USD£2,855GBP
- Report
- November 2019
- 118 Pages
Global
From €4262EUR$4,450USD£3,630GBP
- Drug Pipelines
- December 2022
- 148 Pages
Global
From €10531EUR$10,995USD£8,968GBP
The Oral Insulin market is a subset of the Endocrine and Metabolic Disorders Drugs market. It is composed of drugs that are taken orally to treat diabetes, a condition in which the body does not produce enough insulin or is unable to use the insulin it produces. Oral Insulin is a relatively new form of treatment, and is seen as a more convenient and less invasive alternative to traditional insulin injections. It is also seen as a potential solution to the problem of poor adherence to insulin therapy.
Oral Insulin is still in the early stages of development, and there are currently no approved oral insulin products on the market. However, several companies are researching and developing oral insulin products, and some have already completed clinical trials. Companies in the Oral Insulin market include Novo Nordisk, Sanofi, Eli Lilly, Merck, and Pfizer. Show Less Read more